



## Progress and future challenges in gene vectors, gene therapy systems and gene expressions

Dhinakaran Veeman<sup>1</sup>, Duraisami Dhamodharan<sup>2</sup>, M Varsha Shree<sup>1</sup>, L Natrayan<sup>3</sup>, B Stalin<sup>4</sup>, Shanmugam Ramaswamy<sup>5\*</sup>, Leta Tesfaye Jule<sup>6,7</sup> & R Krishnaraj<sup>7,8</sup>

<sup>1</sup>Centre for Additive Manufacturing, Chennai Institute of Technology, Chennai-600 069, Tamil Nadu, India

<sup>2</sup>Greenlab, Department of Prosthodontics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Chennai-600077, Tamil Nadu, India

<sup>3</sup>Department of Mechanical Engineering, Saveetha School of Engineering, SIMATS, Chennai-602 105, Tamil Nadu, India

<sup>4</sup>Department of Mechanical Engineering, Anna University, Regional Campus Madurai, Madurai-625 019, Tamil Nadu, India

<sup>5</sup>TIFAC, CORE-HD, Department of Pharmacognosy, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty-643 001, Tamil Nadu, India

<sup>6</sup>Department of Physics, College of Natural and Computational Science; <sup>7</sup>Centre for Excellence-Indigenous Knowledge, Innovative Technology Transfer and Entrepreneurship; & <sup>8</sup>Department of Mechanical Engineering, College of Engineering and Technology, Dambi Dollo University, Ethiopia

*Received 13 December 2021; revised 20 October 2022*

Genetic engineering has made sizeable contributions to technical innovation, agriculture, and the development of pharmaceuticals. Various approaches were evolved to control the genetic cloth of cells using both viral and nonviral vector architectures. Gene therapy aims to reverse pathological traits with the aid of the use of viral and nonviral gene shipping mechanisms. Gene transfer motors have made massive strides in becoming more environmentally pleasant, much less risky, and nonimmunogenic, as well as making an allowance for lengthy-time period transgene expression. One of the most tough components of correctly enforcing gene healing treatments in the clinical putting is adjusting gene expression extremely tightly and constantly as and while it's required. This research work will cognizance on using viral vectors for gene concentrated on biological applications with various gene expressions. Due to improvements in viral vector engineering and superior gene regulatory systems to permit and adjust tightly therapeutic gene expression, the technology for using genes to offer a preferred treatment has confirmed to be an effective approach.

**Keywords:** Gene expressions, Gene targeting, Gene therapy, Vectors

Gene therapy is a remedy or prevention technique that includes editing the genes on your body's cells. Genes preserve the DNA code that controls most of your body's shape and function, from growing you taller to directing your organic systems. Genes that are not acting well can cause ailment<sup>1</sup>. By repairing a faulty gene or inserting a new gene, gene remedy pursuits to heal illness or improve your body's capability to fight sickness. Cancer, cystic fibrosis, heart disease, diabetes, haemophilia, and AIDS, among different sicknesses, may additionally gain from gene therapy<sup>2</sup>. How and while gene remedy should be employed is actively being investigated. Gene remedy is presently simplest available as a part of a scientific study within the United States. The capability to make site-precise changes to the human genome has been a purpose in medicine since the discovery of the

gene as the essential unit of heredity<sup>3</sup>. As a result, gene therapy is defined as the capacity to exchange one's genetic fame via the correction of modified (mutated) genes or the advent of web page-precise adjustments that target healing treatment<sup>4</sup>. Developments in genetics and bioengineering enabled using vectors to supply extrachromosomal fabric to target cells, making this remedy possible. Various funding our bodies, including the Department of Biotechnology (DBT), the Department of Science and Technology (DST), the Indian Council of Medical Research (ICMR), and others, are helping gene remedy research in India by way of providing fundamental monetary assistance to scientists and doctors. India is not a long way at the back of different Asian international locations in terms of gene remedy.

One of the approach's key emphases is the optimization of transport vehicles (vectors), which are

\*Correspondence:  
E-mail: Shanmugam\_55555@yahoo.co.in

typically plasmids, nanostructured, or viruses<sup>5</sup>. Because of their talent in invading cells and placing genetic material, viruses are researched extra regularly. However, accelerated immune responses and genetic modifications, especially in germ line cells, are vital worries. Clinical experiments using accepted processes furnished favorable outcomes in *in vivo* studies in somatic cells. The introduction of a regular gene into the genome to update an aberrant gene that reasons contamination is referred to as gene therapy. One of the most crucial challenges within the operation is releasing the gene into the stem cellular<sup>6</sup>. In order to be produced and made available on a huge scale, a molecular carrier referred to as a "vector" is used to launch the gene, which must be very precise, efficient in the release of 1 or extra genes of the sizes required for scientific programs, immune system-unfastened, and purified in massive portions and high concentrations. The vector should not produce allergies or irritation once implanted within the frame; as a substitute, it needs to increase ordinary functioning, correct impairments, or save you dangerous activities. It has to be secure not only for the patient, however additionally for the environment and the experts that work with it. Finally, the vector has to be capable of expressing the gene all through the complete existence of the affected person. The advancement of gene remedy technology in India is seen in (Fig. 1).

The capability to show transgenes on and stale is essential not just when the remedy is now not required, but also whilst negative aspect consequences of the remedy occur<sup>7</sup>. Many regulable systems are presently being developed, and some, like because the tetracycline-based totally transcriptional switch had been effectively employed in *in vivo* preclinical studies<sup>8</sup>. Regardless, there aren't any documented cases of switches being used in a human scientific

test<sup>9</sup>. Under this evaluation, cognizance at the maximum essential regulable structures now in improvement, the gene transfer technology utilized to generate them, and the preclinical fashions in which they were successfully used. We additionally speak the sizable challenges that still want to be overcome earlier than the ones programmable switches may be used in a medical placing. The *in vivo* and *ex vivo* gene therapy along with gene transfer mechanism is shown in (Figs 2 & 3), respectively.

Gene treatment has evolved right into a capacity therapeutic approach for treating and controlling a large variety of troubles<sup>10</sup>. Those transcriptional regulatory systems had been encoded into a spread of viral vectors so one can sell gene expression and enhance gene regulation kinetics. Because of its several benefits, the Tet-regulable device is the maximum broadly used device for modulating gene expression the various extant inducible transcriptional gene regulatory structures. With the use of cellular-kind-unique promoters, tetracycline-based regulable structures can allow regulable targeted gene expression. Furthermore, this device poses no danger to mammalian cells and has no pleiotropic influences on unique cell metabolic pathways. Lentiviruses, adeno-related viruses, first-technology and immoderate-capacity helper-established adenoviruses (HC-advert), and retroviruses have all been proven to embody the Tet regulatory tool, ensuing in a success gene regulation<sup>11</sup>.

This take a look at will provide interest to analyze that have used viral vectors with Tet-regulable systems, as well as growing traits in building superior inducible regulatory structures to decorate gene treatment techniques<sup>12</sup>. The evolution of gene therapy research in India is proven in determine four. For gene treatment for use as a scientific remedy, gene






Fig. 1 — Evolution of gene therapy techniques<sup>13</sup>

Fig. 2 — *In vivo* and *ex vivo* gene therapy<sup>14</sup>Fig. 3 — *In vivo* and *ex vivo* gene transfer mechanism<sup>15</sup>

therapists need to moreover have an excellent expertise of the fast- and lengthy-term protection issues associated with the usage of regulatable gene expression systems, similar to medicinal drug remedy<sup>16</sup>. This involves comparing viral vectors and regulatory mechanisms over extended and brief time periods to make certain secure and green degrees of transgenic expression and immunological response on the host (Fig. 4). With the improvement of extra relaxed viral and nonviral vectors, the prevailing-day trouble for gene therapists is to translate the idea of efficiently controlling restoration gene expression into the health center, similarly to keeping off vector-mediated immune reactions<sup>17</sup>. The classification of gene vectors is represented in (Fig. 5). This is vital

for persistent ailments, which consist of neurodegenerative ailments; activating and silencing recuperation genes may be essential for alleviating normal signs and symptoms of the ailment in a well-timed manner and keeping off detrimental results because of overexpression of these genes<sup>18</sup>. The use of cellular-type-specific and/or targeted vector architectures coupled with effective transcriptional switches to tightly alter recovery gene expression interior specific cells or in a restrained anatomical vicinity could in all likelihood extensively lessen the viable protection risks. This is especially genuine for long-time period neurological sicknesses like more than one sclerosis, Alzheimer's illness, and Parkinson's disease, which exhibit contemporary signs




Fig. 4 — Progression of gene therapy in India<sup>20</sup>




Fig. 5 — Classification of gene vectors<sup>21</sup>

over time<sup>19</sup>. The goal of scientific gene remedy is the use of new Tet-regulatable structures to properly and efficiently manipulate patients' symptoms by means of manner of giving an exogenous medicinal drug that might flip healing gene expression on and rancid as wanted<sup>22</sup> (Table 1).

**Adenoviral vectors**

Adenoviruses are DNA viruses with capsids that contain a 36-kb linear double-stranded DNA genome<sup>23</sup>. The categorization of AAV gene treatment approaches is shown in (Fig. 6). When the fiber protein attaches to the cell surface receptors for coxsackievirus and adenovirus,

Type	Vector	Immunogenic potential	Tropism	Limitation	Major advantage	Ref
Integrating	Retrovirus	Low	Dividing cells only	Potential oncogenicity	Long-term gene expression in dividing cells	24
	Lentivirus	Low	Dividing cells only	Potential oncogenicity	Long-term gene expression in dividing cells	25
Episomal	AAV*	Low	Dividing cells only	Small packaging capacity	Non-inflammatory and non-pathogenic	26
	Herpes simplex virus	High	High in neurons	Transient gene expression in neurons	Large packaging capacity	27
	Adenovirus	High	Dividing cells only	Viral capsid could induce immune response	Efficient transduction of most cells	28




Fig. 6 — AAV capsid gene technique

virus infection occurs<sup>29</sup>. The penton then attaches to the cellular ground's v3 and v5 integrins, allowing the virus to enter via endocytosis. When the Ad virion disassembles within the cell, the viral DNA is released into the nucleus and survives as an episome even while the adenovirus hexon capsid protein remains at the nuclear membrane. The AAV cancer treatment approach is depicted in (Fig. 7).

### Retroviral and lentiviral vectors

RNA viral vectors derived from retroviruses and lentiviruses are a form of RNA virus that, unlike many different viruses, can integrate into the host mobile genome. Because in their capability to mix

into host DNA, those vectors are interesting for gene therapy programs. The transgenic of hobby might be duplicated at some point of the host cell's DNA replication once the vector has been incorporated, taking into consideration long-time period transgene expression (up to two years), that is crucial for chronic therapeutic applications. However, there had been recorded incidences of transgenic expression being steadily suppressed through the years<sup>30</sup>.

### Type 1 herpes simplex vectors

The type 1 herpes simplex virus is a widespread human infection that affects around 80% of the




Fig. 7 — Treatment of cancer by AAV method<sup>32</sup>

population<sup>31</sup>. When an epidemic infects the epithelium, it goes to the CNS ganglia by retrograde axonal transport, where it establishes latency as an episome; when the virus is reactivated, it travels to the epithelium *via* anterograde delivery from the ganglia, where viral replication is active. HSV may infect a person for the rest of their life because it creates latency in the worried system<sup>33</sup>. HSV is a double-stranded DNA molecule with distinct sequences that can be linked by inner repetitions and bordered by terminal repeats<sup>34</sup>. The viral genome contains around eighty genes, half of which are non-essential<sup>35</sup>.

### Nonviral vector-mediated gene delivery

Non-viral delivery techniques are divided into two categories: cationic lipids and cationic polymers. These vectors bind to DNA and produce complexes that can be micro- or nanoparticles. One of the most important elements controlling the vector's effectiveness is the size of the DNA complexes. Biodistribution, cellular internalization, and intracellular trafficking are all significant functions of this protein<sup>36</sup>. The influence of particle size on the above-mentioned attributes has been proven by several study groups. The particle size has an impact on gene transfer even in receptor-mediated endocytosis<sup>37</sup>. Nanoparticles (particles smaller than a micrometer) have been proven to have greater cellular and tissue uptake than micrometer-sized particles. The first stage in the gene transfection process is internalization into the target cell. Endocytosis of a tiny quantity of pDNA by cells is caused by electrostatic repulsions between the cell surface and pDNA. Most synthetic delivery vectors have an

excess of positive charge, which causes the plasmid to condense and become connected with the cell surface through charge interactions. Heparin sulphate proteoglycans that coat the cell surface are primarily responsible for this interaction. Particles with a diameter of less than 200 nm are endocytosed as a result of this binding process. Alternatively, distribution to a specific cell type can be done by conjugating a specific ligand to the delivery system's backbone that has a greater affinity for a certain type of cell surface receptor. The receptor-mediated endocytosis process underpins this mechanism<sup>38</sup>. Figure 8 depicts Gene Delivery through Nonviral Vector-Mediated method.

### Gene expression systems that can be regulated for gene therapy

Gene treatment's success is determined with the aid of way of a variety of things, consisting of the area, period, and amount of gene expression. Regulatory procedures had been developed *in vitro* and *in vivo* to manipulate the temporal expression of a goal gene. The tetracycline law tool is the maximum substantially used and versatile within the imply time. Table 2 shows the temporal specificity for the regulation of transgene expression

Promoters that have been sensitive to a selection of environmental or physiological modifications, consisting of warmth shock, metallic ions, interferons or double-stranded RNA, and steroids, had been first proposed as capability regulatable gene expression systems as shown in (Fig. 9)<sup>39</sup>. A lac operator—IPTG-based totally machine and an FKB12-rapamycin-related protein/FK106 binding protein had been these days examined *in vitro* and *in vivo*. Because plenty of these structures have defects, they're presently inappropriate for clinical gene remedy. The steroid hormone receptor regulatory device, however, seems to have capacity for gene treatment applications and can be similarly investigated.

The most abundant transcription factors in the mammalian proteome are steroid hormone receptors. Endogenous steroid receptor ligands reliably pass through epithelial and plasma membrane barriers. Ligands bind to receptors in the cytoplasm, and the resulting ligand receptor complexes are translocated to the nucleus, where they influence gene expression<sup>40</sup>. Steroid hormone receptor regulating strategies, but, have some of drawbacks. Inducers and repressors of aim genes could have an impact on


Fig. 8 — Gene Delivery through Nonviral Vector-Mediated<sup>42</sup>

Table 2 — Temporal specificity: regulation of transgene expression

Regulating stimulus	Effector molecules	Benefits	Limitations	Ref
Extrinsic stimuli	Tetracycline response element or nuclear hormone receptor elements in a chimeric transcription factor	obtainable in a wide range of viral vectors	It's challenging to get the right dose of regulator medications and apply them at the right time.	43
Dimerizer drugs	Heterodimeric transcription factor	Improved versions have less promoter leakiness.	Concerns about HIV-based systems' safety	44
Intrinsic stimuli	cytokine-inducible gene promoter elements	Remitting-relapsing illnesses are covered.	Experimentation data is scarce.	45
Hypoxia	Hypoxia-inducible transcription factor	Disease activity influences the level and duration of gene expression.	Concerns about HIV-based systems' safety	46

endogenous gene expression in cells<sup>41</sup>. On the opportunity hand, physiological modifications in natural ligand expression may also moreover have a power at the proper song gene expression. Several companies have proposed techniques to address some of the issues associated with steroid hormone receptor modulation<sup>47</sup>.

### Tetracycline-dependent regulatable gene expression systems

In comparison to other techniques for controlling gene expression, the Tet-ON system has several

advantages<sup>48</sup>. For many years, the inducer has been utilized as an antibiotic and has been carefully researched in a medical setting. In preclinical and scientific investigations, it was shown to be safe at the levels necessary for gene activation, with a large margin of safety. Tetracycline (and its counterpart doxycycline) are quickly metabolized and eliminated from the frame, making them a useful therapeutic treatment for increasing transgenic expression, sustaining long-term expression, and reducing transgenic expression. Tet-ON device additives recognize unique DNA sequences, and doxycycline




Fig. 9 — Regulatable Gene Expression Systems

does now not engage with neighborhood proteins, consequently there can be little danger of vast facet results at the same time as the use of this machine<sup>49</sup>. These proteins, as an alternative, may be immunogenic due to the truth that they were created by using the usage of bacteria.

**Gene therapy in the treatment of cardiovascular diseases**

Cardiovascular problems are presently being handled with gene treatment. Cardiovascular ailments are the primary purpose of mortality in Western global locations. In clinical steerage, a diffusion of treatment plans for CVDs are available, but none of them deal with the disorder's underlying purpose. Because the cause of gene remedy is to implant the corrected form of the mutant gene into the precise intention mobile type to repair regular feature, monogenetic CV diseases like immoderate blood stress and hypercholesterolemia are particularly




Fig. 10 — Gene Therapy in Cardiovascular Diseases<sup>50</sup>

important. Gene remedy can deliver a possibility or greater treatment to installation pharmacological restoration techniques in polygenetic CV issues, notwithstanding the problem of changing defective genes, it is shown in (Fig. 10). Gene therapy for CV problems has a number of blessings, which includes the simplicity with which blood arteries can be reached; in maximum conditions, simplest a brief expression of the transfected gene is needed to have a useful natural effect. Gene remedy may also be used as a molecular device to have a observe pathways and mechanisms which may be difficult to apprehend using conventional techniques.

**Glomerulonephritis and Renal Fibrosis**

Glomerulonephritis, or inflammation of the glomeruli, is one of the most prevalent causes of end-stage renal failure<sup>51</sup>. Kidney fibrosis can be caused by severe and chronic inflammation of the glomeruli. Connective tissue growth factor (CTGF) is a four-domained member of the CCN matricellular protein family that modulates growth factor signaling and induces kidney fibrosis. CTGF's four domains can interact with several elements at the same time. The microenvironment varies based on the types of cells and tissues, as well as their differentiation phases. CTGF's biological activities on different types of cells and tissues are influenced by the microenvironment. CTGF is expressed at low levels in the kidney in normal conditions, but it is increased by renal fibrosis. In human kidney biopsy samples, CTGF expression has been found to be elevated in extra-capillary and mesangial lesions of glomerulonephritis. CTGF affects the production of inflammatory mediators, such as cytokines and chemokines, in multiple cell systems through unique signaling pathways, in addition to its role in fibrosis. CTGF is a downstream mediator of TGF- $\beta$ 's profibrotic effects. CTGF has a variety of activities, including cell adhesion and migration, in addition to fibrosis. In glomerulonephritis, CTGF



expression is increased<sup>52</sup>. CTGF deletion alleviates anti-GBM glomerulonephritis in mice through lowering macrophage accumulation. More research is needed to see if CTGF may be used as a possible target for glomerulonephritis therapy. The Gene therapy treatment for renal failure is shown in (Fig. 11).

### Renal transplantation

The primary trouble in kidney transplantation is the immunological response of the recipient's body to the renal graft<sup>53</sup>. Furthermore, the number one ischemia-reperfusion harm increases the immunogenicity of the graft, which has a deleterious impact on each acute and chronic graft failure. Gene remedy may be a probable desire for lowering the immunological reaction after kidney transplantation. To prevent persistent allograft rejection, researchers have tried to regulate the immune reaction. MHC-mismatched




Fig. 11 — Gene therapy for renal failure<sup>54</sup>




Fig. 12 — Gene Therapy for treating Gaucher Disease<sup>55</sup>

kidney allografts had been included from chronic failure in research the use of adeno-associated virus-mediated CTLA4Ig gene switch. One of the critical component reasons of persistent transplant ailment is macrophage interest. In the rat allograft model, targeted on macrophage activity with adenovirus-mediated intrigant over expression of TNFRp55-Ig (TNF receptor p55 immunoglobulin), IL-12p40, and vIL-10 reduces adenovirus-mediated persistent graft harm. Because of its antifibrogenic and anti-inflammatory houses, HGF modified into moreover utilized to deal with persistent renal failure.

### Gene therapy in the treatment of gaucher disease

Gaucher disease (GD) is the most common autosomal recessive lysosomal storage disorder, marked by a decrease in the enzyme -glucosidase (glucocerebrosidase)<sup>56</sup>. A shortage in the synthesis of the enzyme glucocerebrosidase is caused by mutations in the acid glucosidase gene, resulting in a buildup of glucocerebrosides in macrophages, as shown in (Fig. 12). The illness's defining feature is the "Gaucher cells," which may be glucocerebroside-weighted down macrophages. Gaucher cells are large, wrinkled-performing glycolipid-storing cells that can be detected within the BM and spleen. The ordinary treatment for GD is enzyme opportunity remedy (ERT). However, administering biweekly infusions of the recombinant enzyme to patients for the relaxation in their lives is just too steeply-priced. Another treatment technique is substrate reduction treatment (SRT), which includes the usage of inhibitors of ceramide glucosyltransferase to reduce glucosylceramide manufacturing. However, SRT appears to be greater risky and vain than ERT.

### Future challenges

The identity of the perfect metabolic abnormalities that cause neurological illnesses has aided in the development of gene treatment strategies<sup>57</sup>. Furthermore, as fundamental mobile biology, *ex vivo* mobile renovation, and transplantation techniques beautify, new precise cars for the remedy of neurological ailments will emerge. Technical problems with using viral vector systems ought to be addressed. Transduction and infection overall performance, as well as lengthy-term regulatable expression, are sizable future interests. The development of excessive-titer lentiviral vector systems that transduce neural cells contributes to a

developing feeling of wish that neurological illnesses and abnormalities will sooner or later be treated using gene remedy<sup>58-59</sup>.

### Future scope

Gene therapy is now the most fascinating field in biotechnology, both in terms of new accomplishments and the potential that lies ahead. Over the next ten years, unparalleled degrees of control over nucleic acid delivery, immune system management, and specialized human genome alteration technologies – all of which were unimaginable only ten years ago – will completely open up new sectors of medicine. Simultaneously, this first glimpse of a new universe of technical possibilities has spurred entirely new fields of study, such as artificial biology, cell reprogramming, and high-throughput usable genomics, as a way to undoubtedly continue to revolutionize the face of biomedical research. Gene remedy has the capacity to be a possible healing choice for a variety of problems inside the close to future. Gene abnormalities are liable for an estimated 4,000 sickness troubles. Individuals tormented by those problems may stay longer, more healthy lives free of signs and medical expenses if any of those hereditary defects can be remedied by using gene substitution or alteration. Any viral-vector gene remedy's effectiveness hinges on its capability to penetrate past the human immune system's various strains of protection. The immune machine might also understand viral capsids, viral-vector DNA, and even transgenic merchandise as foreign, giving it repeated possibilities to do away with the gene therapy from the body. Immunity towards viral capsids can restriction a gene therapy's effectiveness. Many patients (as much as 60%) may also have preexisting immunity from preceding publicity seeing that maximum viral-vector gene remedies presently employ vectors derived from harmless viruses widespread in humans. Although the clinical outcome of this impact varies relying on the vector serotype employed, many medical-trial sponsors carefully take away people from their trials if they have antibodies to the vector in issue. This may additionally culminate in the general public of patients being ineligible for remedy. Long-term issues for viral-vector gene remedy encompass received immunity to viral vectors. If the identical viral vector is utilized in each condition, patients handled with gene therapy these days won't be capable of get a 2D gene remedy inside the future.

### Conclusion

The movement for the resuscitation of Traditional Systems of Medicine gained traction after India attained independence in 1947. The systems were given formal status and were included into the National Health Care Network to offer health care to the citizens of the country. The Indian government has taken a number of steps to strengthen genetic engineering's status as one of the most important health-care systems for meeting the country's main health-care demands. The generation of unique genetic modifications the usage of homologous vector sequences is a completely specific approach that can be labeled as gene concentrated on. This is in comparison to "gene addition," which takes place when a vector (generally which includes a useful expression cassette) survives as an extrachromosomal episome or integrates at nonhomologous chromosomal net web sites.

- Gene targeting has some of advantages over gene addition, inclusive of the capability to disrupt or modify precise chromosomal sequences, correct transcriptional regulation of vector sequences because of endogenous chromosomal control factors, reduced dangers of insertional mutagenesis and oncogene activation resulting from random integration, and the capability to accurate or remove dominant horrific mutations.
- These scientific studies used each viral and nonviral vectors, but because viral vectors have some of drawbacks, nonviral vectors with better secure and effective transfection are the prevailing cognizance of gene remedy studies.
- The development of DNA vaccines offers a unique method to vaccination and immunotherapy, regarding the delivery of DNA containing the pathogen's genes that create proteins. At present, the bulk of human gene therapy medical research has been achieved to treat cancer.
- An expression machine with a gene of hobby and a gene shipping mechanism makes up a gene medicine. The majority of research has focused on developing a gene delivery generation with excessive transfection efficiency and low toxicity. Continued gene remedy studies would possibly result in the development of a "gene as a medicine alternative" within the close to destiny.

### Conflict of interest

All authors declare no conflict of interest

## References

- 1 Wirth T, Parker N & Yla-Herttuala S, History of gene therapy. *Gene*, 525 (2013) 162.
- 2 Verma IM, Naldini L, Kafri T, Miyoshi H, Takahashi M, Blomer U, Somia N, Wang L & Gage FH, Gene therapy: promises, problems and prospects. *In Genes and Resistance to Disease*, 1 (2000) 147-157.
- 3 Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K & Sadelain M, Gene therapy comes of age. *Science*, 359 (2018) 6372.
- 4 Ma CC, Wang ZL, Xu T, He ZY & Wei YQ, The approved gene therapy drugs worldwide: from 1998 to 2019. *Biotechnol Adv*, 40 (2020) 107502.
- 5 Ginn SL, Amaya AK, Alexander IE, Edelstein M & Abedi MR, Gene therapy clinical trials worldwide to 2017: An update. *J Gene Med*, 20 (2018) 3015.
- 6 Zhigang L, Na D, Dehong C, Jiyong G, Junqing Z & Jin W, Identification of hub genes in airway epithelial cells of asthma patients by WGCNA and PPI network. *Indian J Biochem Biophys*, 59 (2022) 258.
- 7 Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN, Boye SL, Boye SE, George LA, Salabarria S & Corti M, Current clinical applications of *in vivo* gene therapy with AAVs. *Mol Thera*, 29 (2021) 464.
- 8 Varadharajan V, Ganpathi ST, Mandal SK, Prediction of protein-protein interaction networks and druggable genes associated with parkinson's disease. *Indian J Biochem Biophys*, 59 (2022) 39.
- 9 Zhigang Liu, Na Dai, Dehong Chen, Jiyong Gao, Junqing Zheng & Jin Wang, Identification of hub genes in airway epithelial cells of asthma patients by WGCNA and PPI network. *Indian J Biochem Biophys*, 59 (2022) 258.
- 10 Shirley JL, De Jong YP, Terhorst C & Herzog RW, Immune responses to viral gene therapy vectors. *Mol Thera*, 28 (2020) 709.
- 11 Wilson JM & Flotte TR, Moving forward after two deaths in a gene therapy trial of myotubular myopathy. *Hum Gene Thera*, 13 (2020) 695.
- 12 Zhang WW, Li L, Li D, Liu J, Li X, Li W, Xu X, Zhang MJ, Chandler LA, Lin H & Hu A, The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 years in the clinic. *Hum Gene Thera*, 29 (2018)160.
- 13 Bulaklak K & Gersbach CA, The once and future gene therapy. *Nat Commun*, 16 (2020)1.
- 14 Reghupaty SC & Sarkar D, Current status of gene therapy in hepatocellular carcinoma. *Cancers*, 11 (2019) 1265.
- 15 Siddique N, Raza H, Ahmed S, Khurshid Z & Zafar MS, Gene therapy: A paradigm shift in dentistry. *Genes*, 7 (2016) 98. Batty P & Lillicrap D, Advances and challenges for hemophilia gene therapy. *Hum Mol Genet*, 28 (2019) 95.
- 16 Yan Z, McCray Jr PB & Engelhardt JF, Advances in gene therapy for cystic fibrosis lung disease. *Hum Mol Genet*, 28 (2019) 88.
- 17 Doshi BS & Arruda VR, Gene therapy for hemophilia: what does the future hold?. *Thera Adv Hema*, 9 (2018) 273.
- 18 Naso MF, Tomkowicz B, Perry WL & Strohl WR, Adeno-associated virus (AAV) as a vector for gene therapy. *BioDrugs*, 31 (2017) 317.
- 19 High KA, Turning genes into medicines—what have we learned from gene therapy drug development in the past decade?. *Nat Commun*, 11 (2020) 1.
- 20 Caffery B, Lee JS & Alexander-Bryant AA, Vectors for glioblastoma gene therapy: viral & non-viral delivery strategies. *Nanomaterials*, 9 (2019) 105.
- 21 Rai R, Alwani S & Badea I, Polymeric nanoparticles in gene therapy: New avenues of design and optimization for delivery applications. *Polymers*, 11 (2019) 745.
- 22 Ghosh S, Brown AM, Jenkins C & Campbell K, Viral vector systems for gene therapy: a comprehensive literature review of progress and biosafety challenges. *Appl Biosaf*, 25 (2020) 7.
- 23 Patil S, Gao YG, Lin X, Li Y, Dang K, Tian Y, Zhang WJ, Jiang SF, Qadir A & Qian AR, The development of functional non-viral vectors for gene delivery. *Int J Mol Sci*, 20 (2019) 5491.
- 24 Madry H, Gao L, Rey Rico A, Venkatesan JK, Müller Brandt K, Cai X, Goebel L, Schmitt G, Speicher Mentges S, Zurakowski D & Menger MD, Thermosensitive hydrogel based on PEO–PPO–PEO poloxamers for a controlled *in situ* release of recombinant adeno associated viral vectors for effective gene therapy of cartilage defects. *Adv Mat*, 32 (2020) 1906508.
- 25 Wahane A, Waghmode A, Kapphahn A, Dhuri K, Gupta A & Bahal R, Role of lipid-based and polymer-based non-viral vectors in nucleic acid delivery for next-generation gene therapy. *Molecules*, 25 (2020) 2866.
- 26 Wahane A, Waghmode A, Kapphahn A, Dhuri K, Gupta A & Bahal R. Role of lipid-based and polymer-based non-viral vectors in nucleic acid delivery for next-generation gene therapy. *Molecules*, 25 (2020):2866.
- 27 Ku CA & Pennesi ME, The new landscape of retinal gene therapy. *Am J Med Genet C Semin Med Genet*, 184 (2020) 846.
- 28 Tornabene P & Trapani I. Can adeno-associated viral vectors deliver effectively large genes? *Hum Gene Thera*, 31 (2020) 47.
- 29 Bu W & Li Y, Intraductal Injection of Lentivirus Vectors for Stably Introducing Genes into Rat Mammary Epithelial Cells *in vivo*. *J Mam Gla Bio Neopla*, 25 (2020) 389.
- 30 Freedman JC, Parry TJ, Zhang P, Majumdar A, Krishnan S, Regula LK, Malley M, Coghlan S, Yogesha SD, Ramasamy S & Agarwal P, Preclinical Evaluation of a Modified Herpes Simplex Virus Type 1 Vector Encoding Human TGM1 for the Treatment of Autosomal Recessive Congenital Ichthyosis. *J Invest Dermatol*, 141 (2021) 874.
- 31 Lee CS, Bishop ES, Zhang R, Yu X, Farina EM, Yan S, Zhao C, Zeng Z, Shu Y, Wu X & Lei J, Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine. *Genes Dis*, 4 (2017) 43.
- 32 Chan DY, Moralli D, Wheatley L, Jankowska JD & Monaco ZL, Multigene human artificial chromosome vector delivery with herpes simplex virus 1 amplicons. *Exp cell Res*, 388 (2020) 111840.
- 33 Fraefel C & Epstein AL, Preparation of herpes simplex virus type 1 (HSV-1)-based amplicon vectors. *In Herpes Simplex Virus*, 2060 (2020) 91.
- 34 Velarde K, *Herpes Simplex Virus 1 Amplicon Vectors* (Doctoral dissertation, Arizona State University).
- 35 Ediriweera GR, Chen L, Yerbury JJ, Thurecht KJ & Vine KL, Non-Viral Vector-Mediated Gene Therapy for ALS: Challenges and Future Perspectives. *Mol Pharm*, 18 (2021) 2142–2160
- 36 Komuro H, Yamazoe M, Nozaki K, Nagai A & Sasano T. Cardiomyocyte uptake mechanism of a hydroxyapatite

- nanoparticle mediated gene delivery system. *Beilstein J Nanotechnol*, 11 (2020) 1685.
- 37 Ugurlu O, Barlas FB, Evran S & Timur S, The cell-penetrating YopM protein-functionalized quantum dot-plasmid DNA conjugate as a novel gene delivery vector. *Plasmid*, 110 (2020) 102513.
- 38 Spöring M, Finke M & Hartig JS, Aptamers in RNA-based switches of gene expression. *Curr opinion biotechnol*, 63 (2020) 34.
- 39 Zhong G, Wang H, He W, Li Y, Mou H, Tickner ZJ, Tran MH, Ou T, Yin Y, Diao H & Farzan M, A reversible RNA on-switch that controls gene expression of AAV-delivered therapeutics *in vivo*. *Nature biotechnology*, 38 (2020) 169.
- 40 Muhuri M, Maeda Y, Ma H, Ram S, Fitzgerald KA, Tai PW & Gao G, Overcoming innate immune barriers that impede AAV gene therapy vectors. *J Clin Invest*, 131 (2021) 143780.
- 41 Patil S, Gao YG, Lin X, Li Y, Dang K, Tian Y, Zhang WJ, Jiang SF, Qadir A & Qian AR. The development of functional non-viral vectors for gene delivery. *Int J Mol Sci*, 20 (2019) 5491.
- 42 Chen L, Li J, Fan Y, Qiu J, Cao L, Laurent R, Mignani S, Caminade AM, Majoral JP & Shi X. Revisiting cationic phosphorus dendrimers as a nonviral vector for optimized gene delivery toward cancer therapy applications. *Biomacromolecules*, 21 (2020) 2502.
- 43 Takeoka Y, Yurube T & Nishida K. Gene therapy approach for intervertebral disc degeneration: an update. *Neurospine*, 17 (2020) 3.
- 44 Dhinakaran V, Duraisami D, Surendhar GJ, Natrayan L, Stalin B, Shanmugam R, Leta Tesfaye J & Krishnaraj R, Systematic review on nine hallmarks of neurodegenerative disease. *Indian J Biochem Biophys*, 59 (2022) 247.
- 45 Imai E, Takabatake Y, Mizui M & Isaka Y, Gene therapy in renal diseases. *Kidney Int*, 65 (2004) 1551.
- 46 Yamada M, Nagasaki SC, Ozawa T & Imayoshi I, Light-mediated control of Gene expression in mammalian cells. *Neuro res*, 152 (2020) 66.
- 47 Trevisan S, Forestan C, Brojanigo S, Quaggiotti S & Varotto S, Brassinosteroid application affects the growth and gravitropic response of maize by regulating gene expression in the roots, shoots and leaves. *Plant Grow Regul*, 92 (2020) 117.
- 48 Strobel B, Duchs MJ, Blazevic D, Rechtsteiner P, Braun C, Baum-Kroker KS, Schmid B, Ciossek T, Gottschling D, Hartig JS & Kreuz S. A small-molecule-responsive riboswitch enables conditional induction of viral vector-mediated gene expression in mice. *ACS Syn Biol*, 9 (2020) 1292.
- 49 Nishiga M, Qi LS & Wu JC. Therapeutic genome editing in cardiovascular diseases. *Adv drug deliv rev*, 168 (2021)147.
- 50 Güven AT, Idilman IS, Cebrayilov C, Onal C, Kibar MU, Sağlam A, Yıldırım T, Yılmaz R, Altun B, Erdem Y & Karçaaltuncaba M, Evaluation of renal fibrosis in various causes of glomerulonephritis by MR elastography: a clinicopathologic comparative analysis. *Abdom Radiology* 47 (2021) 288.
- 51 Kanemitsu N, Kiyonaga F, Mizukami K, Maeno K, Nishikubo T, Yoshida H & Ito H, Chronic treatment with the (iso-) glutaminyl cyclase inhibitor PQ529 is a novel and effective approach for glomerulonephritis in chronic kidney disease. *Naunyn Schmiedebergs Arch. Pharmacol*, 394 (2021) 751.
- 52 Adapa S, Chenna A, Balla M, Merugu GP, Koduri NM, Daggubati SR, Gayam V, Naramala S & Konala VM, COVID-19 pandemic causing acute kidney injury and impact on patients with chronic kidney disease and renal transplantation. *J Clin Med Res*, 12 (2020) 352.
- 53 Magno AL, Herat LY, Carnagarin R, Schlaich MP & Matthews VB, Current knowledge of IL-6 cytokine family members in acute and chronic kidney disease. *Biomedicines*, 7 (2019) 19.
- 54 Stirmemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, Levade T, Astudillo L, Serratrice J, Brassier A & Rose C. A review of Gaucher disease pathophysiology, clinical presentation and treatments. *Int J Mol Sci*, 18 (2017) 441.
- 55 Liu C, Watkins S, Bahnson A, Barranger JA. 14. Gene Therapy for Gaucher Disease via Genetically Engineered Primary Myoblasts. *In Concepts in Gene Therapy*, 103 (2020) 283
- 56 Azhagiri MK, Babu P, Venkatesan V & Thangavel S, Homology-directed gene-editing approaches for hematopoietic stem and progenitor cell gene therapy. *Stem Cell Res Thera*, 12 (2021) 1.
- 57 Sireesha D, Rosy C, Saipriya K & Venkataraman S, Quorum quenching as a strategy for treating Methicillin Resistant *S. aureus* (MRSA) - Effect of  $\epsilon$ -Polylysine, ethanolic extracts of guava leaves and mango seed kernel. *Indian J Biochem Biophys*, 58 (2021) 171.
- 58 Ritu K, Amit S, Pawan K, Mishra AK & Dinda AK, Surface modifications of biodegradable polymeric nanoparticles and their characterization by advanced electron microscopy techniques. *Indian J Biochem Biophys*, 58 (2021) 321.